Elixir®

MEDICAL CORPORATION

INNOVATION FOR LIFE®

DESyne®

NOVOLIMUS ELUTING CORONARY STENT SYSTEM

INNOVATING *VASCULAR RESTORATION*™

LEADING THE WAY TO NEXT GENERATION DES PLATFORMS

Elixir® MEDICAL CORPORATION

INNOVATION FOR LIFE®

ENGINEERED TO MAXIMIZE DELIVERABILITY & CLINICAL PERFORMANCE

DESyne® maximizes deliverability and is able to deliver superior performance with **the lowest published late lumen loss**[4].

FORMULAX™ Coating Technology

Advanced Drug/Polymer Coating Technology

- Thin polymer and drug matrix coating without the need for a primer coating
- Superior DES clinical performance with excellent safety profile[1]

Lowest Polymer Coating Load[2]

- Reduced risk of adverse clinical events [1]
- Improved polymer biocompatibility[3]

Low Drug Dose

- Sustainable performance with lower drug dose





Elixir® MEDICAL CORPORATION
INNOVATION FOR LIFE®

CLINICAL Performance Sets New Standards

EXCELLA II RCT (n = 210)

Late Lumen Loss at 9 Months



- Significant reduction in late lumen loss, p = 0.001
- Lowest published late lumen loss [4]

Elixir® MEDICAL CORPORATION
INNOVATION FOR LIFE®

CLINICAL Performance Sets New Standards

EXCELLA II RCT (n = 210)

Major Adverse Cardiac Events (MACE) at 3 Years Clinical Follow-up



» MACE defined as Target Lesion Revascularization, Cardiac Death and Myocardial Infarction

Elixir® MEDICAL CORPORATION
INNOVATION FOR LIFE®

CLINICAL Performance Sets New Standards

EXCELLA II RCT (n = 210)

Clinical Follow-up year 1, 2 and 3



» Sustained clinical performance over time

Elixir MEDICAL CORPORATION
INNOVATION FOR LIFE®

CLINICAL Performance Sets New Standards

EXCELLA II RCT (n = 210)

Neointimal Volume Obstruction by IVUS at 9 Months



» Low neointimal volume obstruction

Neointima-free Frame Ratio (% cross-sections without neointima coverage)



» Optimal neointimal coverage with low neointimal volume obstruction

SIZE AVAILABILITY

Stent Diameter (mm)	Stent Length (mm)					
			NEW!		NEW!	NEW!
	14	18	23	28	32	38
2.5	✓	✓	✓	✓	✓	✓
3.0	✓	✓	✓	✓	✓	✓
3.5	✓	✓	✓	✓	✓	✓

INTERNATIONAL (OUS) USE ONLY

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.

EXCELLA BD

SUPERIOR CLINICAL PERFORMANCE



Proven Novolimus drug in a degradable polylactide-based polymer



Advanced drug coating on proven stent design

Superior clinical performance through 6 months*

Angiographic and IVUS Results through 6 months

In-Stent Analysis	Novolimus	Zotarolimus	P value
RVD. mm	$N_{(L)}$=154	$N_{(L)}$= 75	
Post-procedure	2.84±0.43	2.91±0.38	0.20
At 9-months	2.82±0.44	2.70±0.42	0.06
MLD / Late Lumen loss (LLL), (mm)			
Acute gain	1.36±0.40	1.47±0.36	0.047
Acute gain (%)	46.48±11.65	47.51±11.13	0.53
MLD post-procedure	2.48±0.39	2.57±0.37	0.10
MLD at 9-months	2.36±0.48	1.95±0.48	< 0.001
LLL at 9-months	**0.11±0.32**	**0.63±0.42**	**< 0.001**
Loss index	0.08±0.28	0.42±0.27	< 0.001
Diameter Stenosis (%)			
Post-procedure	12±5	11±5	0.34
At 9-months	16±12	28±14	< 0.001
Binary Restenosis (%)			
At 9-months	**1.4% (2/138)**	**7.6% (5/66)**	**0.037**
Volumetric Analysis	$N_{(L)}$=34	$N_{(L)}$=15	
%Neointimal volume obstruction (%)	**4.5±5.1**	**20.9±11.3**	**<0.001**

THE NEXT ADVANCEMENT IN VASCULAR RESTORATION

DESOLVE FIM

Proving Performance with a First-in Man Trial



POST-STENTING (BASELINE)



6 MONTH FOLLOW-UP

DESOLVE NX TRIAL

(ENROLLMENT INITIATED)

- DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System
- Available scaffold sizes: 3.0 x 14mm, 3.0 x 18mm, 3.25 x 14mm, 3.25 x 18mm, 3.5 x 14 mm and 3.5 x 18 mm

DESolve Nx Clinical Trial Design

Single *De Novo* Coronary Artery Lesion
Reference vessel diameter: 2.75 – 3.5mm
Lesion length: <14 mm, DAPT 12 months

↓

DESolve Nx Novolimus Eluting Bioresorbable Coronary Scaffold System

↓

15 sites worldwide
Belgium, Germany, Poland, Brazil and New Zealand
120 patients

Clinical MACE

30d | 6mo | 1yr | 2yr | 3yr | 4yr | 5yr

Angiographic
IVUS, OCT and MSCT

Principal Imaging Endpoint: in-scaffold late lumen loss by QCA at 6 months

Safety Endpoints:

- Clinical: Major Adverse Cardiac Events (cardiac death, target vessel MI, and clinically-indicated TLR), and scaffold thrombosis at 1, 6, and 12 months, 2 – 5 years
- QCA: In-segment late lumen loss, binary restenosis, and percent diameter stenosis at 6 months
- IVUS: In-scaffold percent volume obstruction at 6 months (sub-set)
- OCT: Scaffold and vessel assessment at 6 and 24 months (sub-set)
- MSCT: Vessel assessment at 1 year (sub-set)